Is Welcure Drugs & Pharmaceuticals Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Welcure Drugs & Pharmaceuticals Ltd and arrived at the following conclusion.

Is the current market price of Welcure Drugs & Pharmaceuticals Ltd a good price to buy it?

The 5-year analysis of Welcure Drugs & Pharmaceuticals Ltd's performance infers.

What is Welcure Drugs & Pharmaceuticals Ltd share price return in the past 10 years?

We analysed the performance of Welcure Drugs & Pharmaceuticals Ltd share prices over the last 10 years. Here is what we found out:

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Welcure Drugs & Pharmaceuticals Ltd

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

What is CAGR? What does CAGR table indicate for Welcure Drugs & Pharmaceuticals Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Welcure Drugs&Pharma reports Profit after tax of Rs -0.04 Mln, in the December 2020 quarter

Welcure Drugs & Pharmaceuticals Ltd. | Trading | Healthcare | BSE: 524661 | NSE:

16 Jan 2021

Evaluate

A minor change in the total revenue was seen in the December 2020 quarter. The total revenue for the quarter stood at Rs. 0.00 millions against Rs. 0.00 millions during year ago period.The Net Loss for the quarter ended December 2020 is Rs. -0.04 millions as compared to Net Loss of Rs. -0.11 millions of corresponding quarter ended December 2019 Operating profit Margin for the quarter ended December 2020 improved to -0.04% as compared to -0.11% of corresponding quarter ended December 2019

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202012	201912	% Var	202012	201912	% Var	202003	201903	% Var
Sales	0.00	0.00	0.00	0.81	0.73	10.96	0.83	0.80	3.75
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
PBIDT	-0.04	-0.11	-63.64	0.15	-0.03	-600.00	-0.09	0.04	-325.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PBDT	-0.04	-0.11	-63.64	0.15	-0.03	-600.00	-0.09	0.04	-325.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PBT	-0.04	-0.11	-63.64	0.15	-0.03	-600.00	-0.09	0.04	-325.00
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	-0.04	-0.11	-63.64	0.15	-0.03	-600.00	-0.09	0.04	-325.00
Equity	121.19	121.19	0.00	121.19	121.19	0.00	121.19	135.12	-10.31
PBIDTM(%)	0.00	0.00	0.00	18.52	-4.11	-550.62	-10.84	5.00	-316.87